Dronedarone: A novel antiarrhythmic agent for the treatment of atrial fibrillation

Gabor Z. Duray, Joachim R. Ehrlich, Stefan H. Hohnloser

Research output: Review article

10 Citations (Scopus)

Abstract

Purpose of Review: To describe the electrophysiological profile and the clinical portfolio of dronedarone, a new multichannel-blocking antiarrhythmic drug developed for the treatment of atrial fibrillation. Recent Findings: Dronedarone is a derivative of amiodarone that is free of iodine and less lipophilic. The drug has - as its predecessor - multichannel-blocking efficacy and in addition vasodilating effects. It reduces the incidence of ventricular fibrillation in several experimental models. Dronedarone has undergone thorough clinical evaluation in various patient populations. In two large trials, the drug was shown to postpone the recurrence of atrial fibrillation after cardioversion relative to placebo. In a trial in unstable heart failure patients, there was excess mortality in the dronedarone arm. This trial was stopped prematurely and prompted the conduct of a large outcome study. The ATHENA trial demonstrated a significant reduction in cardiovascular hospitalizations and death in atrial fibrillation patients randomly assigned to receive dronedarone or placebo. This large trial in more than 4600 patients revealed no signs of excess mortality or morbidity in patients receiving dronedarone. Summary: On the basis of the results of five international, multicenter, randomized clinical trials involving nearly 6300 patients, dronedarone was approved by the FDA for treatment of nonpermanent atrial fibrillation to reduce the risk of cardiovascular hospitalization.

Original languageEnglish
Pages (from-to)53-58
Number of pages6
JournalCurrent Opinion in Cardiology
Volume25
Issue number1
DOIs
Publication statusPublished - jan. 1 2010

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Dronedarone: A novel antiarrhythmic agent for the treatment of atrial fibrillation'. Together they form a unique fingerprint.

  • Cite this